Abstract
The prognosis for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) has significantly improved with the use of EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as the widely used first-generation EGFR-TKI, Erlotinib. The association between EGFR exon 19 deletions (ex19del) and prolonged survival in EGFR-TKI-treated patients has previously been widely reported, with median overall survival (OS) of approximately 31 months. Molecular factors indicating prolonged survival are not defined.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
